2025
Personalized frailty risk assessment in long-term survivors of colorectal cancer.
Forman R, Westvold S, Long J, Fan J, Hyslop T, Yasin F, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Cecchini M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized frailty risk assessment in long-term survivors of colorectal cancer. Journal Of Clinical Oncology 2025, 43: 65-65. DOI: 10.1200/jco.2025.43.4_suppl.65.Peer-Reviewed Original ResearchRectal cancer survivorsCancer survivorsElixhauser Comorbidity IndexLong-term survivors of colorectal cancerSurvivors of colorectal cancerClinical prediction modelStage I-III colonCancer diagnosisGastrointestinal cancer survivorsYear 4Area-level povertyAssociated with reduced qualityRisk of frailtyProportion of residentsOnset of frailtyPredictors of frailtyFederal poverty lineIncreased risk of deathAdministrative claims codesSurvivorship managementRisk of deathRetrospective cohort studyAssociated with shorter timePatient raceSevere frailty
2023
Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.Peer-Reviewed Original ResearchConceptsOral anticancer agentsTherapy utilizationMedicare beneficiariesNon-Hispanic white raceMetastatic renal cell carcinomaNon-Hispanic black raceOlder US patientsUS Medicare beneficiariesRenal cell carcinomaLogistic regression modelsTherapy receiptMultivariable adjustmentSystemic therapyMale sexUS patientsCell carcinomaStudy criteriaBlack raceFemale sexPatient raceWhite raceImmunotherapyOutcomes persistSexPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply